MUMBAI, India, Feb. 27 -- Intellectual Property India has published a patent application (202641018304 A) filed by Dr. Srinivas Mulkalapalli; Dr. D. Chitra; Dr. Ghazala Sultan; Ch Sree Kumar; and Sandhya Rani Biswal, Hyderabad, Telangana, on Feb. 18, for 'a deep learning and explainable ai-based multi-omics fusion framework for mapping mechanistic pathways in drug-induced gut-liver crosstalk alterations.'
Inventor(s) include Dr. Srinivas Mulkalapalli; Dr. D. Chitra; Dr. Ghazala Sultan; Ch Sree Kumar; and Sandhya Rani Biswal.
The application for the patent was published on Feb. 27, under issue no. 09/2026.
According to the abstract released by the Intellectual Property India: "The present invention discloses a deep learning and explainable artificial intelligence-based multi-omics fusion framework for mapping mechanistic pathways involved in drug-induced gut-liver crosstalk alterations. The framework integrates genomics, transcriptomics, proteomics, metabolomics, and microbiome datasets using modality-specific encoders and an attention-based fusion layer. An explainable AI module provides interpretable insights through feature attribution and pathway enrichment mapping. The system predicts drug-induced liver toxicity risk while identifying microbial mediators influencing hepatic responses. The invention provides a scalable, interpretable, and biologically informed computational platform applicable in precision medicine, toxicology, and pharmacovigilance."
Disclaimer: Curated by HT Syndication.
